A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2632-2642

  Gyssens, Inge C ^a,b,c   Dryden, Matthew ^d   Kujath, Peter ^e   Nathwani, Dilip ^f   Schaper, Nicolaas ^g   Hampel, Barbara ^h   Reimnitz, Peter ^h   Alder, Jeff ⁱ   Arvis, Pierre ^h  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c HASSELT UNIVERSITY   (Belgium)

^d ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^e University Clinic of Luebeck   (Germany)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h BAYER PHARMA AG   (Germany)

ⁱ BAYER CORPORATION   (United States)

Author keywords

lactams; Fluoroquinolones; Randomized controlled trials; Sequential therapy; Soft tissue infections

Indexed keywords

ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABSCESS DRAINAGE; ACINETOBACTER BAUMANNII; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; BACTEROIDES FRAGILIS; BETA HEMOLYTIC STREPTOCOCCUS; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOLYTIC HEPATITIS; DEBRIDEMENT; DIABETIC FOOT INFECTION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FLATULENCE; GOUT; HEART VENTRICLE EXTRASYSTOLE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORGANELLA MORGANII; MULTICENTER STUDY; NAUSEA; NONHUMAN; PROSPECTIVE STUDY; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SIDE EFFECT; SKIN ABSCESS; SKIN ALLERGY; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE EQUISIMILIS; STREPTOCOCCUS PARASANGUINIS; STREPTOCOCCUS PYOGENES; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; QUINOLINES; SKIN; SKIN DISEASES, BACTERIAL;

EID: 80054679730     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr344     Document Type: Article

References (39)

1. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004; 53 Suppl S2: ii37-50.
2. CDC. Soft tissue infections among injection drug users - San Francisco, California, 1996-2000. MMWR 2001; 50: 381-4.
3. Giordano P, Song J, Pertel P et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005; 26: 357-65.
4. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44: 19-23.
5. Lipsky BA, Weigelt JA, Gupta V et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. J Antimicrob Chemother 2007; 60: 370-6.
6. Eron LJ, Lipsky BA, Low DE et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl S1: i3-17.
7. Woodcock KM, Andrews JM, Boswell FJ et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6.
8. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-11.
9. Guay DRP. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Management 2006; 2: 417-34.
10. Ashour HM, El-Sharif A. Microbial spectrum and antibiotic susceptibility profile of Gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol 2007; 25: 576-9.
11. Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV study). Int J Antimicrob Agents 2009; 33: 52-7.
12. Stearne LE, Vonk AG, Kullberg BJ et al. Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. Antimicrob Agents Chemother 2005; 49: 3668-75.
13. Rubinstein E, Diamantstein L, Yoseph G et al. The effects of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. Clin Microbiol Infect 2000; 6: 678-81.
14. Müller M, Stass H, Brunner M et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9.
15. Burkhardt O, Derendorf H, Jäger D et al. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. Scand J Infect Dis 2006; 38: 904-8.
16. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl B: 83-90.
17. Wise R, Andrews JM, Marshall G et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-10.
18. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J et al. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection 2009; 37: 407-17.
19. Wilson SE, Solomkin JS, Le V et al. A severity score for complicated skin and soft tissue infections derived from Phase III studies of linezolid. Am J Surg 2003; 185: 369-75.
20. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21: 855-9.
21. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004; 20 Suppl 1: S90-5.
22. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981; 2: 64-122.
23. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg 1996; 35: 528-31.
24. McClaine RJ, Husted TL, Hebbeler-Clark RS et al. Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clin Infect Dis 2010; 50: 1120-6.
25. Kvedar JC, Edwards RA, Menn ER et al. The substitution of digital images for dermatologic physical examination. Arch Dermatol 1997; 133: 161-7.
26. Lipsky BA, Giordano P, Choudhri S et al. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 2007; 60: 370-6.
27. Lipsky BA, Itani K, Norden C et al. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
28. Lipsky BA, Armstrong DG, Citron DM et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-703.
29. Dang CN, Prasad YD, Boulton AJ et al. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20: 159-61.
30. Tentolouris N, Petrikkos G, Vallianou N et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 2006; 12: 186-9.
31. Lecornet E, Robert J, Jacqueminet S et al. Preemptive isolation to prevent meticillin-resistant Staphylococcus aureus cross-transmission in diabetic foot. Diabetes Care 2007; 30: 2341-2.
32. Sader HS, Farrell DJ, Jones RN. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents 2010; 36: 28-32.
33. Ferry T, Etienne J. Community acquired MRSA in Europe. BMJ 2007; 335: 947-8.
34. Ball P, Stahlmann R, Kubin R et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-50.
35. Vernaz N, Hill K, Leggeat S et al. Temporal effects of antibiotic use and Clostridium difficile infections. J Antimicrob Chemother 2009; 63: 1272-5.
36. Hensgens MP, Goorhuis A, van Kinschot CM et al. Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 2011; 30: 587-93.
37. Weiss K. Clostridium difficile and fluoroquinolones: is there a link? Int J Antimicrob Agents 2009; 33 Suppl 1: S29-32.
38. Citron DM, Goldstein EJC, Merriam CV et al. Bacteriology of moderate- severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007; 45: 2818-28.
39. EARS-NET 2009. Antimicrobial Resistance Surveillance in Europe 2009. http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf (8 August 2011, date last accessed).